| Literature DB >> 24886513 |
Martin Andersen, Mikael Boesen, Karen Ellegaard, Robin Christensen, Kalle Söderström, Niels Søe, Pieter Spee, Ulrik Gw Mørch, Søren Torp-Pedersen, Else Marie Bartels, Bente Danneskiold-Samsøe, Nina Vendel, Lars Karlsson, Henning Bliddal.
Abstract
INTRODUCTION: Despite the widespread use of magnetic resonance imaging (MRI) and Doppler ultrasound for the detection of rheumatoid arthritis (RA) disease activity, little is known regarding the association of imaging-detected activity and synovial pathology. The purpose of this study was to compare site-specific release of inflammatory mediators and evaluate the corresponding anatomical sites by examining colour Doppler ultrasound (CDUS) and MRI scans.Entities:
Mesh:
Substances:
Year: 2014 PMID: 24886513 PMCID: PMC4078218 DOI: 10.1186/ar4557
Source DB: PubMed Journal: Arthritis Res Ther ISSN: 1478-6354 Impact factor: 5.156
Figure 1Schematic of patient flow through the study, imaging procedures carried out, number of joints synovectomised and number of established synovial cultures with corresponding imaging modalities used. MCP, Metacarpal phalangeal joint; MRI, Magnetic resonance imaging; N, Total number of patients; n, Number of synovial explant samples; PIP, Proximal interphalangeal joint; US, Ultrasound.
Patient demographics and clinical characteristics
| Females, | 19 (76%) |
| Mean age ± SD, yr (IQR) | 56.2 ± 14.9 (26 to 77) |
| Disease duration, yr | 12.3 [4.0 to 14.1] (0.9; 42.7) |
| RF-positive, | 21 (84%) |
| Anti-CCP-positive, | 22 (88%) |
| Mean DAS-28-CRP score (0 to 10) | 4.8 ± 1.3 [2.2 to 6.8] |
| CRP, mg/L | 20.9 [4 to 30] (1; 117) |
| VAS global (scale 0 to 100) | 62.5 [41 to 83] |
| Tender joint count, 28 joints | 7.1 [4 to 9] (0; 25) |
| Swollen joint count, 28 joints | 7.8 [4 to 9] (1; 21) |
| DMARD monotherapy | |
| MTX, | 2 (8%) |
| SZS, | 3 (12%) |
| LFU, | 2 (8%) |
| DMARD combination treatment | |
| MTX + SZS, | 4 (16%) |
| MTX + SZS + HCQ, | 3 (12%) |
| Biologic DMARDs (%) | 8 (32%) |
| Prednisolone monotherapy, 5 mg/day | 2 (8%) |
| No DMARDs (%) | 1 (4%) |
aCCP, Cyclic citrullinated peptide; CRP, C-reactive protein; DAS28, Disease Activity Score in 28 joints; HCQ, Hydroxychloroquine; LFU, Leflunomide; MCP, Metacarpophalangeal joint; MTX, Methotrexate; PIP, Proximal interphalangeal joint; RF, Rheumatoid factor; SD, Standard deviation; SZS, Sulphasalazine; VAS, Visual Analogue Scale. Values are median [Q1 to Q3], (min; max) or mean ± SD unless otherwise stated.
Overview of imaging observations and explant activity
| | | |
| Focal RAMRIS BME score, 0-3 | | |
| Wrist | 12 (34) | 1.8 [0.8 to 3.0] (0.0; 3.0) |
| MCP | 4 (4) | 2.0 [1.3 to 2.8] (0.0; 3.0) |
| PIP | 3 (4) | 2.0 [1.0 to 2.5] (1.0; 2.5) |
| Total | 19 (42) | 1.5 [1.0 to 2.8] (0.0; 3.0) |
| CFmax, 0-1 | | |
| Wrist | 17 (48) | 0.08 [0.02 to 0.23] (0.0; 0.86) |
| MCP | 4(4) | 0.12 [0.05 to 0.34] (0.03; 0.52) |
| PIP | 3(4) | 0.06 [0.03 to 0.07](0.0: 0.08) |
| Total | 24 (56) | 0.08 [0.01 to 0.21] (0.0; 0.86) |
| | | |
| MCP-1 | | |
| Wrist | 17 (48) | 4,848 [1,138 to 15,000] (240.5; 46,450) |
| MCP | 6 (6) | 2,444 [840 to 11,175] (240.5; 31,336) |
| PIP | 3 (4) | 2,082 [986 to 2,707] (348; 3,053) |
| Total | 25 (58) | 3,865 [1,138 to 12,915] (240.5; 46,450) |
| IL-6 | | |
| Wrist | 17 (48) | 8,465 [1,321 to 39469] (72.5; 266,857) |
| MCP | 6 (6) | 4,969 [391 to 37,496] (72.5; 534,340) |
| PIP | 3 (4) | 11,901 [1,761 to 29,205] (732; 37,400) |
| Total | 25 (58) | 8,031 [1,156 to 37,400] (72.5; 534,340) |
| IL-8 | | |
| Wrist | 17 (48) | 21,129 [5,649 to 96,401] (26,5; 137,001) |
| MCP | 6 (6) | 21,132 [5,405 to 48,883] (4,571; 137,001) |
| PIP | 3 (4) | 20,730 [6,388 to 50,750] (2,017; 70,800) |
| Total | 25 (58) | 21,129 [5,503 to 89,643] (26.5; 137,001) |
| MIP-1β | | |
| Wrist | 17 (48) | 1,812 [530 to 6,828] (366.5; 28,420) |
| MCP | 6 (6) | 1,078 [577 to 2,786] (366.5; 19,120) |
| PIP | 3 (4) | 555 [354 to 1,724] (366.5; 2,705) |
| Total | 25 (58) | 1,331 [502 to 5,196] (366.5; 28,420) |
Depicting an overview of the imaging activity and synovial explant mediator production. Avr. = average, CFmax = colour fraction measured in the systole, IL-6 = Interleukin 6, IL-8 = Interleukin 8, IQR = Interquartile range (3rd quartile – 1st quartile), Max. = maximum, MCP = Metacarpo-phalangeal joint, MCP-1 = macrophage chemoattractant protein 1, Min. = minimum, MIP-1b = Macrophage inflammatory protein 1 beta, no. = number , PIP = Proximal interphalangeal joint, RAMRIS BME Score = Rheumatoid Arthritis Magnetic Ressonance Bone Marrow Oedema Score.
1 Mean ± Standard deviation.
Figure 2Scatterplots depicting synovitis, defined as synovial perfusion by maximal systolic colour fraction and by magnetic resonance imaging using the rheumatoid arthritis magnetic resonance imaging score for synovitis vs. synovial explant release after 72 hours in culture. The statistically significant plots are shown. For the remaining plots, see Additional file 3. Rheumatoid arthritis magnetic resonance imaging scores (RAMRIS) for synovitis are shown in (a) and (b). (a) Interleukin 6 (P = 0.04, approximate ρ = 0.50). (b) Macrophage inflammatory protein 1β (P = 0.02, approximate ρ =0.63). Maximal systolic colour fraction (CFmax) values are shown in (c) and (d). (c) Monocyte chemoattractant protein 1 (P = 0.009, approximate ρ = 0.41). (d) Macrophage inflammatory protein 1β (P = 0.02, approximate ρ = 0.38).
Statistical associations with rheumatoid arthritis explant mediator release at 72 hours vs. at time of imaging
| 0.009 (0.41) | 0.17 (0.48) | 0.01 (0.42) | 0.03 (0.31) | |
| 0.23 (0.22) | 0.04 (0.50) | 0.04 (0.25) | 0.03 (0.35) | |
| 0.09 (0.27) | 0.08 (0.58) | 0.16 (0.27) | 0.07 (0.43) | |
| 0.02 (0.38) | 0.02 (0.63) | 0.95 (0.35) | 0.62 (0.30) |
aCFmax, Maximal systolic colour fraction; BME, Bone marrow oedema; IL, Interleukin; MCP-1, Monocyte chemoattractant protein 1; MIP-1, Macrophage inflammatory protein 1β; RAMRIS, Rheumatoid arthritis magnetic resonance imaging score.
A mixed model has been used for the statistical analysis: P < 0.05 was considered significant. In the reduced model, covariates were excluded if P > 0.10. This table contains the data from the reduced models. The full models including stepwise covariate elimination steps and model optimization transformation can be found in the supplementary files.
The pre-specified covariates included in the statistical model: Joint Synovectomized = Wrist, MCP or PIP; Synovectomy position = Ulnar, central, radial, or mixed for pooled synovectomy positions; Side = left or right;
Approx. rho = approximated Spearman’s rho; RAMRIS BME = RAMRIS bone marrow edema component; RAMRIS Erosion = RAMRIS erosion score component; RAMRIS synovitis = RAMRIS synovitis score component; IL-6 = Interleukin 6; IL-8 = Interleukin 8, MCP-1 = Monocyte chemoattractant protein 1; MIP-1b = Macrophage Inflammatory Protein 1 beta.
Figure 3Scatterplots depicting bone marrow oedema and bone erosion measured by the rheumatoid arthritis magnetic resonance imaging score vs. synovial explant release after 72 hours in culture. The statistically significant plots are shown. For the remaining plots, see Additional file 4. Bone marrow oedema (BME) rheumatoid arthritis magnetic resonance imaging scores (RAMRIS) are shown in (a) and (b). (a) Monocyte chemoattractant protein 1 (P = 0.01, approximate ρ = 0.42). (B) Interleukin 6 (P = 0.04, approximate ρ = 0.25). Bone erosion RAMRIS scores are shown in (c) and (d). (c) Monocyte chemoattractant protein 1 (P = 0.03, approximate ρ = 0.31). (d) Interleukin 6 (P = 0.03, approximate ρ = 0.35).